Designation highlights significant regulatory milestone and provides a potential pathway to seven years of U.S. market exclusivity LA JOLLA, CA, June 18, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc....
Live webcast fireside chat with Marc Hertz, PhD, Chief Executive Officer, on Wednesday, May 20, 2026 Register for the event here LA JOLLA, CA, May 18, 2026 (GLOBE NEWSWIRE) -- GRI Bio,...
Phase 2a data show zero cough and 60% lower treatment-related diarrhea than placebo despite higher nintedanib use in the active arm – suggesting GRI-0621 may mitigate nintedanib-related GI-toxicities...
Issued claims further strengthen global intellectual property portfolio supporting immune cell modulation platform and expand strategic presence in a high-growth international market LA JOLLA, CA,...
Access the “What This Means” segment here LA JOLLA, CA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing...
Register for the two-day virtual event here
– Live video webcast on Wednesday, February 11 th at 1:00 PM EST LA JOLLA, CA, Feb. 05, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”),...
Company reported $8.2 million in cash and cash equivalents at December 31, 2025 and raised additional $6.5 million in gross proceeds in January 2026 Balance sheet strengthened to fund operations...
Multiple Independent Molecular Signals Converge to Validate GRI-0621 as a Potential Disease-Modifying Therapy LA JOLLA, CA, Jan. 28, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI...
Issued Claims Protect Distinct Molecular Designs with Broad Therapeutic Potential Across Inflammatory, Fibrotic, and Autoimmune Diseases LA JOLLA, CA, Jan. 26, 2026 (GLOBE NEWSWIRE) -- GRI Bio,...